Among them, inhibitors of ACC, FAS, DGAT2 (diacylglycerol O-acyltransferase 2), FXR (Farnesoid X receptor) agonists, and recombinant FGF19 were found to effectively reduce the steatosis phenotype, thus supporting the concept that monocellular epithelial liver organoids serve as a suitable model for drug candidates targeting de novo lipogenesis. Here, DGAT2 is linked to steatosis.